Skip to content

A Disposable Device NAS to Treat Obstructive Sleep Apnea and Snoring

A Disposable Device NAS to Treat Obstructive Sleep Apnea and Snoring

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02928770
Enrollment
32
Registered
2016-10-10
Start date
2015-02-28
Completion date
2017-12-31
Last updated
2019-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea, Snoring

Brief summary

The purpose of this research study is to test a new approach for treating patients with obstructive sleep apnea and/or snoring. The new nasal device, nastent (NAS: nasal airway stent), appears to be a useful alternative or additive treatment.

Detailed description

The nasal stent basically helps to splint the soft palate open. Subjects have a baseline (diagnostic) sleep study without wearing the device. Subjects are then fitted with the device and then subjects wear the device for at least 7 nights during their sleep while at home. Subjects then return for a repeat in-laboratory sleep study while wearing the device. The primary outcome is to assess the effectiveness of the device by change in the apnea-hypopnea index (number of sleep-related abnormal breathing events per hour of sleep) while wearing the device compared to baseline.

Interventions

DEVICENastent

Use of the device while at home and in the sleep lab

Sponsors

Seven Dreamers Laboratories
CollaboratorUNKNOWN
Stanford University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adults that are 18 years of age or older who had a prior sleep-study within the past 6 months that confirmed a diagnosis of obstructive sleep apnea, and with body mass index less than 30 kg/m2.

Exclusion criteria

* Children, pregnant women, homeless, economically disadvantaged individuals, and those who are unable to comprehend or understand English, or follow instructions were excluded. Persons with body mass index equal or greater than 30 kg/m2 were excluded.

Design outcomes

Primary

MeasureTime frameDescription
Apnea-Hypopnea Index (AHI)In-lab sleep study obtained at least 7 nights following use of the device at homeAbnormal breathing events (apneas = complete pauses in oronasal airflow; hypopneas = decreases in oronasal airflow) per hour of sleep. This is measured through polysomnography (sleep study) by a nasal thermistor and oral pressure sensor.

Countries

United States

Participant flow

Participants by arm

ArmCount
Nastent
A baseline sleep study is obtained from the subject, without wearing the device. The individual wears the device at home for at least 7 nights, and then returns to the sleep lab for an in-laboratory sleep study while wearing the device. Nastent: Use of the device while at home and in the sleep lab
30
Total30

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyWithdrawal by Subject2

Baseline characteristics

CharacteristicNastent
Age, Continuous56.3 years
STANDARD_DEVIATION 15.3
Apnea-Hypopnea Index34.9 events/hour
STANDARD_DEVIATION 23.8
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
28 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
8 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
Race (NIH/OMB)
White
18 Participants
Region of Enrollment
United States
30 participants
Sex: Female, Male
Female
3 Participants
Sex: Female, Male
Male
27 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 30
other
Total, other adverse events
0 / 30
serious
Total, serious adverse events
0 / 30

Outcome results

Primary

Apnea-Hypopnea Index (AHI)

Abnormal breathing events (apneas = complete pauses in oronasal airflow; hypopneas = decreases in oronasal airflow) per hour of sleep. This is measured through polysomnography (sleep study) by a nasal thermistor and oral pressure sensor.

Time frame: In-lab sleep study obtained at least 7 nights following use of the device at home

ArmMeasureValue (MEAN)Dispersion
NastentApnea-Hypopnea Index (AHI)30.0 events/hourStandard Deviation 20.3
p-value: 0.0559t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026